1
|
Dong W, Chen H, Wang L, Cao X, Bu X, Peng Y, Dong A, Ying M, Chen X, Zhang X, Yao L. Exploring the shared genes of hypertension, diabetes and hyperlipidemia based on microarray. BRAZ J PHARM SCI 2020. [DOI: 10.1590/s2175-97902020000118333] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Affiliation(s)
- Wenzhu Dong
- Zhejiang Chinese Medical University, P.R. China; Taizhou Central Hospital, P.R. China
| | | | - Lu Wang
- Zhejiang Chinese Medical University, P.R. China
| | | | - Xiawei Bu
- Zhejiang Chinese Medical University, P.R. China
| | - Yan Peng
- Zhejiang Chinese Medical University, P.R. China
| | | | | | - Xu Chen
- Taizhou Central Hospital, P.R. China
| | - Xin Zhang
- Taizhou Central Hospital, P.R. China
| | - Li Yao
- Zhejiang Chinese Medical University, P.R. China
| |
Collapse
|
2
|
Azharuddin M, Adil M, Ghosh P, Kapur P, Sharma M. Periostin as a novel biomarker of cardiovascular disease: A systematic evidence landscape of preclinical and clinical studies. J Evid Based Med 2019; 12:325-336. [PMID: 31769219 DOI: 10.1111/jebm.12368] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/13/2019] [Revised: 08/17/2019] [Accepted: 11/03/2019] [Indexed: 11/27/2022]
Abstract
BACKGROUND Periostin is a matricellular protein, expressed in various normal adult and fetal tissues. Recently, elevated periostin levels have been reported in heart failure, coronary artery disease, and stroke. However, there is lack of clinical studies to clarify the prognostic significance of systemic periostin levels in cardiovascular diseases (CVDs). The aim of the study was to perform a systematic review of published evidence on periostin and CVDs, and to clarify the diagnostic and prognostic significance of systemic periostin levels in CVDs. METHODS A systematic search on PubMed was performed to identify relevant articles from inception to December 2018. The eligible studies evaluating the periostin expression and periostin levels in animal and human studies. RESULTS A total of 24 relevant studies, including both animal and human data, were included. Periostin is significantly observed in myocardium tissue of failing hearts compared with control, and is also expressed in atherosclerotic plaques. Systemic periostin levels were significantly correlated with cardiac function and severity of CVD in several studies. A clinical study also observed positive correlation between periostin and N-terminal pro b-type natriuretic peptide (NT-proBNP), highly sensitive troponin (hsTnT), and ST2 cardiac biomarker. Studies reported limited adjustment for potential confounders. CONCLUSIONS The evidence of current review support potential role of periostin in the pathophysiology of CVD. However, scarcity of data regarding the clinical use of periostin levels in the current management of CVDs further creates room for the future investigation. Therefore, further studies warrant to clarify its potential role, if any, as a novel cardiac biomarker.
Collapse
Affiliation(s)
- Md Azharuddin
- Division of Pharmacology, Department of Pharmaceutical Medicine, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India
| | - Mohammad Adil
- Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India
| | - Pinaki Ghosh
- Department of Pharmacology, Poona College of Pharmacy, Bharati Vidyapeeth, Pune, India
| | - Prem Kapur
- Department of Medicine, Hamdard Institute of Medical Sciences and Research, Jamia Hamdard, New Delhi, India
| | - Manju Sharma
- Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India
| |
Collapse
|
3
|
Patel MS, Miranda-Nieves D, Chen J, Haller CA, Chaikof EL. Targeting P-selectin glycoprotein ligand-1/P-selectin interactions as a novel therapy for metabolic syndrome. Transl Res 2017; 183:1-13. [PMID: 28034759 PMCID: PMC5393932 DOI: 10.1016/j.trsl.2016.11.007] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/05/2016] [Accepted: 11/13/2016] [Indexed: 12/22/2022]
Abstract
Obesity-induced insulin resistance and metabolic syndrome continue to pose an important public health challenge worldwide as they significantly increase the risk of type 2 diabetes and atherosclerotic cardiovascular disease. Advances in the pathophysiologic understanding of this process has identified that chronic inflammation plays a pivotal role. In this regard, given that both animal models and human studies have demonstrated that the interaction of P-selectin glycoprotein ligand-1 (PSGL-1) with P-selectin is not only critical for normal immune response but also is upregulated in the setting of metabolic syndrome, PSGL-1/P-selectin interactions provide a novel target for preventing and treating resultant disease. Current approaches of interfering with PSGL-1/P-selectin interactions include targeted antibodies, recombinant immunoglobulins that competitively bind P-selectin, and synthetic molecular therapies. Experimental models as well as clinical trials assessing the role of these modalities in a variety of diseases have continued to contribute to the understanding of PSGL-1/P-selectin interactions and have demonstrated the difficulty in creating clinically relevant therapeutics. Most recently, however, computational simulations have further enhanced our understanding of the structural features of PSGL-1 and related glycomimetics, which are responsible for high-affinity selectin interactions. Leveraging these insights for the design of next generation agents has thus led to development of a promising synthetic method for generating PSGL-1 glycosulfopeptide mimetics for the treatment of metabolic syndrome.
Collapse
Affiliation(s)
- Madhukar S Patel
- Department of Surgery, Massachusetts General Hospital, Boston, Mass; Department of Surgery, Beth Israel Deaconess Medical Center, Boston, Mass; Harvard Medical School, Boston, Mass
| | - David Miranda-Nieves
- Department of Surgery, Beth Israel Deaconess Medical Center, Boston, Mass; Harvard Medical School, Boston, Mass; Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Mass
| | - Jiaxuan Chen
- Department of Surgery, Beth Israel Deaconess Medical Center, Boston, Mass; Harvard Medical School, Boston, Mass
| | - Carolyn A Haller
- Department of Surgery, Beth Israel Deaconess Medical Center, Boston, Mass; Harvard Medical School, Boston, Mass
| | - Elliot L Chaikof
- Department of Surgery, Beth Israel Deaconess Medical Center, Boston, Mass; Harvard Medical School, Boston, Mass.
| |
Collapse
|
4
|
Manolescu DC, Jankowski M, Danalache BA, Wang D, Broderick TL, Chiasson JL, Gutkowska J. All-trans retinoic acid stimulates gene expression of the cardioprotective natriuretic peptide system and prevents fibrosis and apoptosis in cardiomyocytes of obese ob/ob mice. Appl Physiol Nutr Metab 2014; 39:1127-36. [PMID: 25017112 DOI: 10.1139/apnm-2014-0005] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
In hypertensive rodents, retinoic acid (RA) prevents adverse cardiac remodelling and improves myocardial infarction outcome, but its role in obesity-related changes of cardiac tissue are unclear. We hypothesized that all-trans RA (ATRA) treatment will improve the cardioprotective oxytocin-natriuretic peptides (OT-NP) system, preventing apoptosis and collagen accumulation in hearts of ob/ob mice, a mouse model of obesity and insulin resistance. Female 9-week-old B6.V-Lep/J ob/ob mice (n = 16) were divided into 2 groups: 1 group (n = 8) treated with 100 μg of ATRA dissolved in 100 μL of corn oil (vehicle) delivered daily (∼2 μg·g body weight(-1)·day(-1)) by stomach intubation for 16 days, and 1 group (n = 8) that received the vehicle alone. A group of nonobese littermate mice (n = 9) served as controls. Ob/ob mice exhibited obesity, hyperglycaemia, and downregulation of the cardiac OT-NP system, including the mRNA for the transcription factor GATA4, OT receptor and brain NP, and the protein expression for endothelial nitric oxide synthase. Hearts from ob/ob mice also demonstrated increased apoptosis and collagen accumulation. ATRA treatment induced weight loss and decreased adipocytes diameter in the visceral fat, thus reducing visceral obesity, which is associated with a high risk for cardiovascular disease. RA treatment was associated with a reduction in hyperglycemia and a normalization of the OT-NP system's expression in the hearts of ob/ob mice. Furthermore, ATRA treatment prevented apoptosis and collagen accumulation in hearts of ob/ob mice. The present study indicates that ATRA treatment was effective in restoring the cardioprotective OT-NP system and in preventing abnormal cardiac remodelling in the ob/ob mice.
Collapse
Affiliation(s)
- Daniel-Constantin Manolescu
- a Laboratory of Nutrition and Cancer, Centre de recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Université de Montréal, Québec, Canada
| | | | | | | | | | | | | |
Collapse
|
5
|
Forterre A, Jalabert A, Berger E, Baudet M, Chikh K, Errazuriz E, De Larichaudy J, Chanon S, Weiss-Gayet M, Hesse AM, Record M, Geloen A, Lefai E, Vidal H, Couté Y, Rome S. Proteomic analysis of C2C12 myoblast and myotube exosome-like vesicles: a new paradigm for myoblast-myotube cross talk? PLoS One 2014; 9:e84153. [PMID: 24392111 PMCID: PMC3879278 DOI: 10.1371/journal.pone.0084153] [Citation(s) in RCA: 112] [Impact Index Per Article: 11.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2013] [Accepted: 11/19/2013] [Indexed: 12/17/2022] Open
Abstract
Exosomes are nanometer-sized microvesicles formed in multivesicular bodies (MVBs) during endosome maturation. Exosomes are released from cells into the microenvironment following fusion of MVBs with the plasma membrane. During the last decade, skeletal muscle-secreted proteins have been identified with important roles in intercellular communications. To investigate whether muscle-derived exosomes participate in this molecular dialog, we determined and compared the protein contents of the exosome-like vesicles (ELVs) released from C2C12 murine myoblasts during proliferation (ELV-MB), and after differentiation into myotubes (ELV-MT). Using a proteomic approach combined with electron microscopy, western-blot and bioinformatic analyses, we compared the protein repertoires within ELV-MB and ELV-MT. We found that these vesicles displayed the classical properties of exosomes isolated from other cell types containing components of the ESCRT machinery of the MVBs, as well as numerous tetraspanins. Specific muscle proteins were also identified confirming that ELV composition also reflects their muscle origin. Furthermore quantitative analysis revealed stage-preferred expression of 31 and 78 proteins in ELV-MB and ELV-MT respectively. We found that myotube-secreted ELVs, but not ELV-MB, reduced myoblast proliferation and induced differentiation, through, respectively, the down-regulation of Cyclin D1 and the up-regulation of myogenin. We also present evidence that proteins from ELV-MT can be incorporated into myoblasts by using the GFP protein as cargo within ELV-MT. Taken together, our data provide a useful database of proteins from C2C12-released ELVs throughout myogenesis and reveals the importance of exosome-like vesicles in skeletal muscle biology.
Collapse
Affiliation(s)
- Alexis Forterre
- CarMeN Laboratory (INSERM 1060, INRA 1362, INSA) University of Lyon, Faculté de Médecine Lyon-Sud, Oullins, France
| | - Audrey Jalabert
- CarMeN Laboratory (INSERM 1060, INRA 1362, INSA) University of Lyon, Faculté de Médecine Lyon-Sud, Oullins, France
| | - Emmanuelle Berger
- CarMeN Laboratory (INSERM 1060, INRA 1362, INSA) University of Lyon, Faculté de Médecine Lyon-Sud, Oullins, France
| | - Mathieu Baudet
- CEA, IRTSV, Laboratoire Biologie à Grande Echelle, Grenoble, France
- INSERM, U1038, Grenoble, France
- Grenoble Alpes University, IRTSV, Laboratoire Biologie à Grande Echelle, Grenoble, France
| | - Karim Chikh
- CarMeN Laboratory (INSERM 1060, INRA 1362, INSA) University of Lyon, Faculté de Médecine Lyon-Sud, Oullins, France
| | - Elisabeth Errazuriz
- Centre Commun d’Imagerie de Laënnec (CeCIL), SFR Santé Lyon-Est, University of Lyon, Lyon, France
| | - Joffrey De Larichaudy
- CarMeN Laboratory (INSERM 1060, INRA 1362, INSA) University of Lyon, Faculté de Médecine Lyon-Sud, Oullins, France
| | - Stéphanie Chanon
- CarMeN Laboratory (INSERM 1060, INRA 1362, INSA) University of Lyon, Faculté de Médecine Lyon-Sud, Oullins, France
| | - Michèle Weiss-Gayet
- Centre de Génétique et de Physiologie Moléculaire et Cellulaire (CGPhiMC), CNRS UMR5534, University of Lyon, Lyon, France
| | - Anne-Marie Hesse
- CEA, IRTSV, Laboratoire Biologie à Grande Echelle, Grenoble, France
- INSERM, U1038, Grenoble, France
- Grenoble Alpes University, IRTSV, Laboratoire Biologie à Grande Echelle, Grenoble, France
| | - Michel Record
- INSERM-UMR 1037, Centre de Recherche en Cancerologie de Toulouse (CRCT), Toulouse, France
| | - Alain Geloen
- CarMeN Laboratory (INSERM 1060, INRA 1362, INSA) University of Lyon, Faculté de Médecine Lyon-Sud, Oullins, France
| | - Etienne Lefai
- CarMeN Laboratory (INSERM 1060, INRA 1362, INSA) University of Lyon, Faculté de Médecine Lyon-Sud, Oullins, France
| | - Hubert Vidal
- CarMeN Laboratory (INSERM 1060, INRA 1362, INSA) University of Lyon, Faculté de Médecine Lyon-Sud, Oullins, France
| | - Yohann Couté
- CEA, IRTSV, Laboratoire Biologie à Grande Echelle, Grenoble, France
- INSERM, U1038, Grenoble, France
- Grenoble Alpes University, IRTSV, Laboratoire Biologie à Grande Echelle, Grenoble, France
| | - Sophie Rome
- CarMeN Laboratory (INSERM 1060, INRA 1362, INSA) University of Lyon, Faculté de Médecine Lyon-Sud, Oullins, France
- * E-mail:
| |
Collapse
|